Tags

Type your tag names separated by a space and hit enter

Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.
BJU Int. 2008 Jul; 102(1):28-32.BI

Abstract

OBJECTIVES

To compare the prostate-specific antigen (PSA) recurrence (PSAR) rates in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP) or radical retropubic prostatectomy (RRP).

PATIENTS AND METHODS

Data from 797 consecutive patients who had RALP or RRP between August 2003 and January 2007 were retrieved from our database. Age, race, body mass index, PSA level, estimated blood loss (EBL), clinical and pathological stage, biopsy and pathological Gleason score, lymph node involvement, positive surgical margin (PSM) status, and prostate weight were compared between the groups. Multivariate analysis (logistic and Cox regression) was used to adjust for differences in clinical and pathological features when comparing the risk for PSM and PSAR.

RESULTS

In all, 362 men had RALP and 435 had RRP; the mean follow-up was 1.09 and 1.37 years, respectively. RALP patients had a significantly lower clinical stage, Gleason score and EBL (P < 0.001). There was no significant difference in PSM between RALP and RRP in univariate (P = 0.701) and multivariate analyses (P = 0.095). The risk of PSAR for patients undergoing RALP or RRP was not significantly different after adjusting for clinical (hazard ratio 0.82, 95% confidence interval 0.48-1.38; P = 0.448) and pathological differences (0.94, 0.55-1.61; P = 0.824).

CONCLUSIONS

Patients undergoing RALP had a lower EBL and lower-risk disease. After adjusting for differences in clinical and pathological features, there was no significant difference in early PSAR between patients undergoing RALP or RRP.

Authors+Show Affiliations

Duke Prostate Center, Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

18384634

Citation

Schroeck, Florian R., et al. "Comparison of Prostate-specific Antigen Recurrence-free Survival in a Contemporary Cohort of Patients Undergoing Either Radical Retropubic or Robot-assisted Laparoscopic Radical Prostatectomy." BJU International, vol. 102, no. 1, 2008, pp. 28-32.
Schroeck FR, Sun L, Freedland SJ, et al. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. BJU Int. 2008;102(1):28-32.
Schroeck, F. R., Sun, L., Freedland, S. J., Albala, D. M., Mouraviev, V., Polascik, T. J., & Moul, J. W. (2008). Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. BJU International, 102(1), 28-32. https://doi.org/10.1111/j.1464-410X.2008.07607.x
Schroeck FR, et al. Comparison of Prostate-specific Antigen Recurrence-free Survival in a Contemporary Cohort of Patients Undergoing Either Radical Retropubic or Robot-assisted Laparoscopic Radical Prostatectomy. BJU Int. 2008;102(1):28-32. PubMed PMID: 18384634.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. AU - Schroeck,Florian R, AU - Sun,Leon, AU - Freedland,Stephen J, AU - Albala,David M, AU - Mouraviev,Vladimir, AU - Polascik,Thomas J, AU - Moul,Judd W, Y1 - 2008/04/02/ PY - 2008/4/4/pubmed PY - 2008/7/25/medline PY - 2008/4/4/entrez SP - 28 EP - 32 JF - BJU international JO - BJU Int VL - 102 IS - 1 N2 - OBJECTIVES: To compare the prostate-specific antigen (PSA) recurrence (PSAR) rates in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP) or radical retropubic prostatectomy (RRP). PATIENTS AND METHODS: Data from 797 consecutive patients who had RALP or RRP between August 2003 and January 2007 were retrieved from our database. Age, race, body mass index, PSA level, estimated blood loss (EBL), clinical and pathological stage, biopsy and pathological Gleason score, lymph node involvement, positive surgical margin (PSM) status, and prostate weight were compared between the groups. Multivariate analysis (logistic and Cox regression) was used to adjust for differences in clinical and pathological features when comparing the risk for PSM and PSAR. RESULTS: In all, 362 men had RALP and 435 had RRP; the mean follow-up was 1.09 and 1.37 years, respectively. RALP patients had a significantly lower clinical stage, Gleason score and EBL (P < 0.001). There was no significant difference in PSM between RALP and RRP in univariate (P = 0.701) and multivariate analyses (P = 0.095). The risk of PSAR for patients undergoing RALP or RRP was not significantly different after adjusting for clinical (hazard ratio 0.82, 95% confidence interval 0.48-1.38; P = 0.448) and pathological differences (0.94, 0.55-1.61; P = 0.824). CONCLUSIONS: Patients undergoing RALP had a lower EBL and lower-risk disease. After adjusting for differences in clinical and pathological features, there was no significant difference in early PSAR between patients undergoing RALP or RRP. SN - 1464-410X UR - https://www.unboundmedicine.com/medline/citation/18384634/Comparison_of_prostate_specific_antigen_recurrence_free_survival_in_a_contemporary_cohort_of_patients_undergoing_either_radical_retropubic_or_robot_assisted_laparoscopic_radical_prostatectomy_ L2 - https://doi.org/10.1111/j.1464-410X.2008.07607.x DB - PRIME DP - Unbound Medicine ER -